SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™
SonoPath.com
1-800-838-4268 info@sonopath.com



PATIENT
Clark Holland

SPECIES
Canine

BREED
Mix

SEX
Male Neutered

AGE
13.5 years

WEIGHT
78lbs

INTERPRETED BY
Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY
Sharri Reffi, CVT

HOSPITAL NAME
Marsh Animal Hospital

REFERRING VET
Dr. Milwicki

INVOICE
32420

DATE
8/17/23

PRESENTING CLINICAL SIGNS

History: Recheck echo. Recent episodes of poor appetite. Gastritis. Grade 1/6 heart murmur. Coughing, panting.
-Current medications: Started Lasix 8/15 pm; Gabapentin.
-Abnormal PE/Chem/CBC/UA Results: ALP 1565, USG 1.022.
-Pertinent previous echo findings (5/2022 EL): No LAE, mild LVE, FS: 20%, LV: 5.6.
-CXR report (Idexx): Cardiomegaly. PV distention. Concern for CHF.
-ECG repot (Idexx): Sinus tachycardia with tall R waves.

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Severe left ventricular dilation with diminished systolic function. Decreased LV wall thickness with increased sphericity. Moderate to severe left atrial enlargement. The mitral valve appears normal in form and function, with no obvious prolapse into the left atrial lumen. Moderate central mitral regurgitation secondary to annular stretch. Decreased velocity. Mild tricuspid regurgitation. Moderate right atrial and ventricular dilation. TR velocity consistent with mild pulmonary hypertension. The aortic valve is normal in morphology and mobility. No subvalvular ridge present; normal LVOT velocity. No aortic insufficiency. Normal pulmonic valve with trace pulmonic insufficiency seen. No pericardial or pleural effusion noted. No obvious cardiac tumors. Premature beats noted throughout.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	4.5	3.1	1.9	2.0	12	20	1.7
CANINE CARDIAC PARAMETERS	**HR** (BPM)	**AV VMAX** (m/s)	**PV MAX** (m/s)	**BODY WEIGHT** (kg)	**LA** 2D short axis Base view (cm)	**LVIDd** Avg; 2D and m-mode short axis (cm)	**LVIDs** Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	100	0.7	0.5	35.4	4.6	6.7	5.9
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
**Note: All measurements based upon multi-modal images and methods. An average value is reported.*				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

Adapted from June Boon, Veterinary Echocardiography, 1998
Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435
Hansson et al, Vet Rad and Ultrasound 2002
Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Unfortunately, this patient has significant cardiomyopathy and systolic dysfunction that has progressed from the previous study. There is dilation and volume overload of both the left and right heart resulting in insufficiency of the mitral and tricuspid valves. The severity of dysfunction



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Clark Holland

SPECIES
Canine

BREED
Mix

SEX
Male Neutered

AGE
13.5 years

WEIGHT
78lbs

INTERPRETED BY
Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY
Sharri Reffi, CVT

HOSPITAL NAME
Marsh Animal Hospital

REFERRING VET
Dr. Milwicki

INVOICE
32420

DATE
8/17/23

and pump failure is severe, and the patient is at high risk for decompensating into congestive failure. Patient will always be at risk for right and/or left-sided CHF, development of arrhythmias/syncope and/or sudden death going forward. Premature beats are noted throughout the study, which are not mentioned in the ECG report. Reassessing the ECG is advised.

Systolic failure can be primary in nature (DCM) or secondary to taurine deficiency, myocarditis, hypothyroidism, tachycardia-induced cardiomyopathy, or infiltrative disease such as lymphoma. While primary disease is certainly possible, consider testing for primary causes that may be treatable. A troponin (cTnI) level can be submitted to further investigate infiltrative/inflammatory contribution (myocarditis). Additionally, a taurine level may be helpful (screen for malabsorption issue), and a thorough diet history given the recent correlation with grain free/boutique brand/exotic ingredient diets. Finally, further systemic evaluation for underlying infiltrative contribution such as neoplasia is also reasonable (abdominal ultrasound, etc.).

Regardless of cause, prognosis is guarded to poor at this stage in the disease process, with an average survival time of <6 months. The only treatable cause of systolic failure is diet/taurine deficiency, which is uncommon on commercially formulated dog foods. If the diet is of concern, highly recommend immediate diet change and taurine supplement regardless of blood taurine results. Please see the FDA website for more information.

Given that the patient is experiencing respiratory signs and based upon the CXR report, **full cardiac supportive medications are recommended as below due to high risk for decompensation.** Cases of systolic failure are at high risk for malignant tachyarrhythmias (such as VT or rapid AF) and sudden death, and this should be expressed to the owner. Activity restriction is advised.

Elective anesthesia is not advised due to high risk for complications.

Omega fatty acid supplementation and mild salt restriction may be of some long-term benefit. Monitor for development of a cough, worsening labored breathing, abdominal distention, exercise intolerance or collapse episodes in the future. Monitoring of sleeping breathing rates at home is recommended to assess response to medications and recurrence of CHF in the future.

PLAN:
Reassess ECG as discussed. Baseline BP recommended. Initiate aldosterone antagonist Spironolactone 1-2mg/kg PO q12h. Institute furosemide 1mg/kg PO q12h. Institute Pimobendan 0.3mg/kg PO q12h. Institute taurine 1000mg PO q12h. Diet history/change as discussed.

Monitor a renal panel and blood pressure in 1-2 weeks to ensure tolerance. If BP >130mmHg, institute ACEI 0.5mg/kg PO q12h. Consider cTnI, taurine level, AUS as discussed above.

A recheck echocardiogram is recommended in 4-6 months to screen for progression, sooner if clinical issues arise in the interim.

SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™






SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Clark Holland

SPECIES
Canine

BREED
Mix

SEX
Male Neutered

AGE
13.5 years

WEIGHT
78lbs

INTERPRETED BY
Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY
Sharri Reffi, CVT

HOSPITAL NAME
Marsh Animal Hospital

REFERRING VET
Dr. Milwicki

INVOICE
32420

DATE
8/17/23

IMAGES






The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com